The Fruits of AI Drug Abundance: Indigestion in the Near Term (lifescivc.com)

AI is revolutionizing the biopharma space, promising more efficient drug discovery and faster delivery of medicines. However, experts predict that the immediate outcome will be an overwhelming surge of drug candidates—known as Drug Abundance—exacerbating existing R&D productivity challenges rather than alleviating them. This phenomenon mirrors the Genomics Bubble's impact on the industry in the early 2000s, where a flood of novel targets led to increased failure rates and costs due to insufficient validation. The democratization of molecular design through AI enables smaller teams to partake in drug development, circumventing traditional barriers of extensive resources and experience. Yet, the majority of current AI applications rely on existing drug discovery knowledge, meaning they tend to target well-established biological pathways and known drug scaffolds. This reliance risks worsening the "me-too drug" phenomenon, where numerous candidates compete over the same validated targets, creating excess competition and drawing crucial resources away from innovative, novel drug discovery efforts. Consequently, while AI may accelerate the pace of drug development, its impact on overall R&D productivity may remain limited, necessitating a reevaluation of strategies among biopharma companies to navigate this new landscape effectively.